- Home
- OCSL vs RCUS Comparison
OCSL vs RCUS Comparison
Compare OCSL & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCSL
- RCUS
- Stock Information
- Founded
- OCSL 2007
- RCUS 2015
- Country
- OCSL United States
- RCUS United States
- Employees
- OCSL N/A
- RCUS N/A
- Industry
- OCSL Finance: Consumer Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- OCSL Finance
- RCUS Health Care
- Exchange
- OCSL Nasdaq
- RCUS Nasdaq
- Market Cap
- OCSL 1.1B
- RCUS 1.2B
- IPO Year
- OCSL 2008
- RCUS 2018
- Fundamental
- Price
- OCSL $13.54
- RCUS $19.61
- Analyst Decision
- OCSL Hold
- RCUS Buy
- Analyst Count
- OCSL 6
- RCUS 8
- Target Price
- OCSL $15.20
- RCUS $27.63
- AVG Volume (30 Days)
- OCSL 871.3K
- RCUS 1.9M
- Earning Date
- OCSL 11-18-2025
- RCUS 10-28-2025
- Dividend Yield
- OCSL 11.62%
- RCUS N/A
- EPS Growth
- OCSL N/A
- RCUS N/A
- EPS
- OCSL 0.55
- RCUS N/A
- Revenue
- OCSL $334,099,000.00
- RCUS $240,000,000.00
- Revenue This Year
- OCSL N/A
- RCUS N/A
- Revenue Next Year
- OCSL N/A
- RCUS N/A
- P/E Ratio
- OCSL $25.19
- RCUS N/A
- Revenue Growth
- OCSL N/A
- RCUS N/A
- 52 Week Low
- OCSL $12.44
- RCUS $6.50
- 52 Week High
- OCSL $16.53
- RCUS $22.11
- Technical
- Relative Strength Index (RSI)
- OCSL 49.00
- RCUS 66.39
- Support Level
- OCSL $13.49
- RCUS $18.63
- Resistance Level
- OCSL $14.05
- RCUS $20.68
- Average True Range (ATR)
- OCSL 0.25
- RCUS 1.25
- MACD
- OCSL -0.02
- RCUS -0.02
- Stochastic Oscillator
- OCSL 37.52
- RCUS 57.03
About OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.